US-based clinical-stage biotechnology company Cardiff Oncology has announced positive initial data from its randomised Phase II clinical trial evaluating onvansertib in combination with standard ...

Cardiff Oncology, Inc. announced positive results from its ongoing first-line clinical trial of onvansertib in RAS-mutated metastatic colorectal cancer (mCRC), showcasing a 64% response rate in ...

Cardiff Oncology is advancing onvansertib for first-line treatment in RAS-mutated CRC, driven by promising trial data. A seamless Phase 3 trial is planned, with FDA feedback expected in the second ...

“We were excited to report that patients on the 30mg onvansertib dose arm demonstrated a 64% response rate, compared to a 33% response rate in the control arm. In the experimental arm, we ...

Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40 million ...